382 Index
attention-deficit/hyperactivity disorder
(ADHD), 56–64
additional features, 58
aetiology and pathogenesis, 56
assessment of symptoms, 58
causation, 60–1
classification, 27 ,28
comorbidity, 34 , 37, 137, 235
defining characteristics, 7, 17, 56–7
diagnosis, 59–60, 70, 71 , 302
prevalence, 33 , 37, 56
prognosis, 63
and substance use/abuse, 206
treatment, 61–3, 339
autistic spectrum disorders (ASD), 27 , 28,
45–55
aetiology and pathogenesis, 51–3
assessment considerations, 49
associated features, 48–9
characteristics, 6, 7–8, 46–7
differential diagnosis, 49–51, 59, 71, 143,
196 , 247
epidemiology, 45–6
prevalence, 33 , 37, 40–1, 45
prognosis, 54
treatment, 53–4
autonomy, 188
avoidant disorder, 100
behavioural disorders/symptoms, 5
comorbidity, 37, 219
prevalence, 33 , 37, 71–2
behavioural family therapy, 348
behavioural genetics, 272, 274
interpreting, 275–7
behaviourally based parent training, 348
behaviourally based programmes/therapies,
328–35
applications, 62, 76, 237, 339
assessment, 329–30
criticisms, 334
evaluation, 334–5
goal negotiations, 330–1
implementation, 333–4
interventions and techniques, 97, 98, 305 ,
331–3
benzodiazepines, 168, 169, 325
bereavement, 105, 129–30, 284
binge drinking, 208
binge eating disorder, 203
bipolar disorder, 110
causation, 113
classical and juvenile-specific criteria, 112,
113–14
epidemiology, 112–13
treatment, 113, 324–5
birth order, 287
bladder training, 154, 156
Bowlby, John, 96, 129, 259–61
brain disorders, 239–43
prognosis and treatment, 242
and psychiatric disorders, 240–1
Brief Strategic Family Therapy, 208–9, 359
British Ability Scale (BAS), 233
bulimia nervosa, 202
bullying, 292–4
buproprion, 62, 139
Cambridge Longitudinal Study, 79–80, 82
cannabis, 197, 204
causality, 271
cerebral palsy, 73, 230, 236, 239, 240, 240 , 255
Child Attachment Interview, 265
Children Act (1989), 224, 361
chromosomal abnormalities, 232, 233
chronic fatigue syndrome (CFS), 178–9
cigarette smoking, 204, 208
circadian sleep–wake cycle disorder, 166–7
circular causality, 344, 345
circular questioning, 355, 356–7
classical conditioning, 96, 328
classification, 22–30
aims and purpose, 22–3
dimensions v. categories, 23–5, 66–7
of individuals v. families, 26
pervasive v. situational, 25–6
phenomenology, 23
see alsodiagnostic groupings
clomipramine, 134, 139, 305 , 322
clonidine, 62, 139, 322
clozapine, 197–8, 324
cluster analysis, 25
cognitive development, factors affecting, 189,
219
cognitive therapy
aggression, 338
anxiety and fear, 97, 98, 338
attention-deficit/hyperactivity disorder, 339
depression, 337–8
intellectually disabled children and
adolescents, 237
cognitive-behavioural therapy (CBT), 337
anxiety disorders, 100
attention-deficit/hyperactivity disorder, 62
depression, 106
obsessive-compulsive disorder, 134
stress disorders, 127
communication impairment, 46–7
community-focused programmes, 76–7
comorbidity, 34 , 37, 59, 69, 105, 137, 257, 307
complex problems/solutions, 303–4
conduct disorder (CD), 7, 27 , 65, 69 ,70
ICD-10 criteria,68–9
prevalence, 71–2, 311
prevention, 76–7, 315–16
and substance use/abuse, 206
see alsodisruptive behavioural disorders
confusional arousals (during sleep), 167
congenital risk, 277, 278
congenital syndromes, 19, 51, 233, 236
constipation, 160
contingency management, 97, 98
conversion disorders, 179–80
coping mechanisms, 289–90